secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2023-09-06T23:59:59+00:00
Accession:  0000950170-23-046574
Event type: leadership
Sentiment:  negative
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroGen CMO Mark Eisner resigns; search underway for replacement
-----------------------------------------------------------------

- CMO Mark Eisner resigns effective Sept 8, 2023; departure voluntary with no disagreement.
- Eisner to serve as consultant through Oct 11, 2023 at $15K/month; equity awards continue vesting.
- Company has initiated search for a new Chief Medical Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000095017023046574/0000950170-23-046574-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000095017023046574/fgen-20230831.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-046574

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer